Navigation Links
Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrine's anti-PS Vascular Targeting Antibodies
Date:4/14/2008

-Combination of a Bavituximab Equivalent and an Agent that Re-Activates the Tumor Suppressor P53 Inhibited Tumor Growth Synergistically in Preclinical

Breast Cancer Models-

SAN DIEGO and TUSTIN, Calif., April 14 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) announced today that a preclinical study being presented by an independent team of investigators at the 2008 Annual Meeting of the American Association for Cancer Research (AACR) further illustrates the broad anti-tumor potential of its anti-phosphatidylserine (anti-PS) vascular targeting antibodies. The study by Dr. Yayun Liang, Dr. Salman Hyder and colleagues at the University of Missouri describes promising anti-cancer activity observed when a mouse equivalent to the company's Phase II anti-PS antibody bavituximab was combined with an investigational agent that re-activates the tumor suppressor p53, which is turned off in many tumors. Bavituximab is a monoclonal antibody that is believed to work by selectively destroying the blood vessels supporting tumor growth and spread and by reversing the ability of tumors to suppress the body's natural immune response.

"This study highlights the broad anti-cancer potential of our anti-PS vascular targeting platform," said Steven W. King, president and CEO of Peregrine. "Numerous preclinical studies have shown the potential efficacy of our anti-PS antibodies in combination with both existing and novel therapies for the treatment of cancer. This new study further illustrates the potential versatility of our anti-PS antibodies in combination cancer therapy. We look forward to future clinical studies of bavituximab and other anti-PS antibodies in a broad range of anti-cancer regime
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
3. Siemens Preclinical Imaging System Helps The Methodist Hospital in Houston Further Its Research Mission
4. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
5. NicOx and Ferrer Present Promising Clinical and Preclinical Results in Dermatology
6. Isis Reports Preclinical Data Supporting Liver Safety of ISIS 301012
7. Preclinical Data on Lead MEK Inhibitor, RDEA119, to be Presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
8. KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model
9. Tezampanel, TorreyPines Therapeutics Lead Compound, Reduced Muscle Spasticity and Rigidity in Preclinical Study Conducted at University of California, San Diego
10. Telik Announces Presentation of Preclinical Data on Dual Inhibitors of Aurora Kinases and VEGFR2
11. CorNova Preclinical Results of Valecor Platinum(TM) Coronary Stent Studies Presented at TCT 2007 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Va. , Dec. 23, 2014  The ... diastolic blood pressure target for people with diabetes ... moderate or high doses of statins, in keeping ... management enacted by the American College of Cardiology ... are reflected in the most recent changes to ...
(Date:12/24/2014)... CHAPEL HILL, N.C. , Dec. 23, 2014 /PRNewswire/ ... marketplace success. As the key link between the medical ... will grow even more in the coming years as ... relationships. According to research by benchmarking ... and MSLs can gain an important edge is by ...
(Date:12/22/2014)... DUBLIN , Dec. 22, 2014 Research and ... addition of the "US Self-monitoring Blood Glucose Market" ... http://photos.prnewswire.com/prnh/20130307/600769 This market insight focuses ... in the United States . Reimbursement ... studied. Thorough product analyses for more than 73 SMBG ...
Breaking Medicine Technology:New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 2New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 3New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 4Role of Medical Science Liaisons Evolving in Medical Device Sector 2US Self-monitoring Blood Glucose Market 2
... MIVI-TRUST Phase III Program, Confirming... -- LEUVEN, Belgium, September 6, 2010 ... ... ... ,; var first_result; // Results are keyed by longUrl, so we need to grab the first one. ...
... China, Sept. 3 /PRNewswire-Asia-FirstCall/ -- ... ... var ... by longUrl, so we need to grab the first one. for (var r in data.results) { first_result ...
Cached Medicine Technology:ThromboGenics Presents Positive Pooled Results from the MIVI-TRUST Phase III Program, Confirming Microplasmin's Potential to Transform the Treatment of Retinal Disorders 2ThromboGenics Presents Positive Pooled Results from the MIVI-TRUST Phase III Program, Confirming Microplasmin's Potential to Transform the Treatment of Retinal Disorders 3ThromboGenics Presents Positive Pooled Results from the MIVI-TRUST Phase III Program, Confirming Microplasmin's Potential to Transform the Treatment of Retinal Disorders 4ThromboGenics Presents Positive Pooled Results from the MIVI-TRUST Phase III Program, Confirming Microplasmin's Potential to Transform the Treatment of Retinal Disorders 5ThromboGenics Presents Positive Pooled Results from the MIVI-TRUST Phase III Program, Confirming Microplasmin's Potential to Transform the Treatment of Retinal Disorders 6ThromboGenics Presents Positive Pooled Results from the MIVI-TRUST Phase III Program, Confirming Microplasmin's Potential to Transform the Treatment of Retinal Disorders 7ThromboGenics Presents Positive Pooled Results from the MIVI-TRUST Phase III Program, Confirming Microplasmin's Potential to Transform the Treatment of Retinal Disorders 8ThromboGenics Presents Positive Pooled Results from the MIVI-TRUST Phase III Program, Confirming Microplasmin's Potential to Transform the Treatment of Retinal Disorders 9ThromboGenics Presents Positive Pooled Results from the MIVI-TRUST Phase III Program, Confirming Microplasmin's Potential to Transform the Treatment of Retinal Disorders 10China Sky One Medical Updates Financial Guidance for 2010 2China Sky One Medical Updates Financial Guidance for 2010 3China Sky One Medical Updates Financial Guidance for 2010 4China Sky One Medical Updates Financial Guidance for 2010 5China Sky One Medical Updates Financial Guidance for 2010 6China Sky One Medical Updates Financial Guidance for 2010 7China Sky One Medical Updates Financial Guidance for 2010 8
(Date:12/24/2014)... 24, 2014 Dr. Vu Ho, a ... of his practice and med-spa with the addition of ... list of cosmetic treatments and services. , “Silk Peel ... skin,” says Dr. Ho. “As a result it can ... wrinkles, sun spots, discolorations or blemishes.” , Similar to ...
(Date:12/24/2014)... (PRWEB) December 24, 2014 Mike ... sat down with Derek Fenwick, PT, MBA, GCS, ... that will stem from the passing of the ... (IMPACT Act). In this taping of the Infinicast, the ... XVIII of the Social Security Act to standardize post-acute ...
(Date:12/24/2014)... -- A new, injectable weight-loss drug has been approved ... agency on Tuesday approved Saxenda (liraglutide) for adults who ... have at least one weight-related health condition, such as ... Patients taking the drug, made by Novo Nordisk, ... the FDA noted. "Obesity is a public health ...
(Date:12/24/2014)... Steven Reinberg HealthDay Reporter ... guidelines from the American Diabetes Association (ADA) call for giving ... diabetes to help prevent heart disease. These new standards ... Cardiology and American Heart Association, which also recommend giving low- ... disease, including people with diabetes. "We agree that the ...
(Date:12/24/2014)... Texas (PRWEB) December 24, 2014 ... Industry is a professional and in-depth research report ... report introduces COC basic information, including its definition, ... analysis, news analysis, etc. This report also presents ... etc. Production is separated by regions, technology and ...
Breaking Medicine News(10 mins):Health News:Dr. Vu Ho Expands Facial Plastic Surgery Practice to Include New Skin Care Treatment 2Health News:Latest Episode of Infinicast Features Infinity Rehab President Discussing IMPACT Act of 2014 and Changes for Post-Acute Therapy Providers in 2015 2Health News:FDA Approves New Weight-Loss Drug 2Health News:FDA Approves New Weight-Loss Drug 3Health News:Nearly All Diabetics Should Be on Cholesterol-Lowering Drugs: Experts 2Health News:Nearly All Diabetics Should Be on Cholesterol-Lowering Drugs: Experts 3Health News:COC/ Cyclic Olefin Copolymer Market: Global 2015-2020 Forecasts & Research Report Now at DeepResearchReports.com 2Health News:COC/ Cyclic Olefin Copolymer Market: Global 2015-2020 Forecasts & Research Report Now at DeepResearchReports.com 3
... released new clinical guidelines for the treatment of exacerbations ... literature on current clinical practices. "This is the ... practices for pulmonary exacerbation of cystic fibrosis," said Susanna ... and director of the Cystic Fibrosis Center at Children,s ...
... N.C. Studies by researchers at Wake Forest University ... receptor in immature rats leads to profound, rapid brain ... mature. The N-methyl-D-aspartate (NMDA) receptor is activated ... released by brain cells. This allows calcium to enter ...
... at-risk American adults who would benefit from vaccination against seasonal ... believe they do not need them and are not inclined ... intend to take up the vaccine, nearly half get around ... Corporation* in Arlington, USA, and her team. Their work (1) ...
... prescriptions issued by GPs has been caused by a year ... drugs on a long-term basis, according to researchers from the ... printed edition of British Medical Journal ( BMJ ... number of new patients diagnosed with depression over 11 years, ...
... chance of success , THURSDAY, Oct. 22 (HealthDay News) -- ... offer the best chance of success with in vitro fertilization ... selecting embryos for implantation in the mother,s womb is highly ... IVF failure or multiple pregnancies," Dr. Emre Seli, an associate ...
... medication leads to better outcome, researchers say , ... say they have a better treatment for patients ... standard therapy. , Their study finds that treatment ... better short-term survival and with lower toxicity than ...
Cached Medicine News:Health News:New clinical guidelines for exacerbations in cystic fibrosis 2Health News:General anesthetics lead to learning disabilities in animal models 2Health News:General anesthetics lead to learning disabilities in animal models 3Health News:Flu shots not to be sneezed at 2Health News:Assessing Embryo Metabolism May Aid IVF Success 2Health News:Study Finds Less Toxic Treatment for Myeloma 2
... chemiluminescence assay for the measurement ... serum. Growth Hormone (GH) is ... the anterior pituitary gland under ... hormone releasing hormone (GHRH) and ...
... the sulfate ester of DHEA, derived from ... DHEA in adrenal and extradrenal tissues. DHEA ... the adrenal cortex, and is a precursor ... relatively weak androgenic activity, which for unsulfated ...
... The DHEA-S ELISA kit is based ... separation. An unknown amount of DHEA-S present ... of DHEA-S conjugated with horse-radish peroxidase compete ... DHEA-S antiserum coated onto the wells. After ...
EL-RF-IgM is high sensitivity quantitative rheumatoid factor IgM....
Medicine Products: